Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 18, 2006, Pages 2505-2520

  Van de Wal, R M A ^a   Voors, A A ^b   Gansevoort, R T ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Cardiovascular risk factors; Microalbuminuria; Renin angiotensin system

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LERCANIDIPINE; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ACUTE KIDNEY FAILURE; ALBUMINURIA; ANGIONEUROTIC EDEMA; ARTERIAL PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG WITHDRAWAL; ENDOCRINE DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INSULIN RESISTANCE; LOW DRUG DOSE; META ANALYSIS; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK MANAGEMENT; SIDE EFFECT; SMOKING; SYSTEMATIC REVIEW; URINARY EXCRETION; VASCULAR ENDOTHELIUM;

ALBUMINURIA; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SERUM ALBUMIN;

EID: 33845567354     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.18.2505     Document Type: Review

References (170)

1. VIBERTI GC, HILL RD, JARRETT RJ, ARGYROPOULOS A, MAHMUD U, KEEN H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet (1982) 1:1430-1432.
2. SVENDSEN PA, OXENBOLL B, CHRISTIANSEN JS: Microalbuminuria in diabetic patients-a longitudinal study. Acta Endocrinol. Suppl. (Copenh) (1981) 242:53-54.
3. MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. (1984) 310:356-360.
4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. (2002) 39:S1-S266.
5. BIANCHI S, BIGAZZI R, CAMPESE VM: Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am. J. Kidney Dis. (1999) 34:973-995.
6. VERHAVE JC, HILLEGE HL, DE ZEEUW D, DE JONG PE: How to measure the prevalence of microalbuminuria in relation to age and gender? Am. J. Kidney Dis. (2002) 40:436-437.
7. GANSEVOORT RT, VERHAVE JC, HILLEGE HL et al.: The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int. Suppl. (2005) S28-S35.
8. DEEN WM: What determines glomerular capillary permeability? J. Clin. Invest. (2004) 114:1412-1414.
9. BRENNER BM, HOSTETTER TH, HUMES HD: Molecular basis of proteinuria of glomerular origin. N. Engl. J. Med. (1978) 298:826-833.
10. BRENNER BM, BOHRER MP, BAYLLS C, DEEN WM: Determinants of glomerular permselectivity: Insights derived from observations in vivo. Kidney Int. (1977) 12:229-237.
11. ROWE DJ, DAWNAY A, WATTS GF: Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann. Clin. Biochem. (1990) 27(Pt 4):297-312.
12. CHRISTENSEN EI, BIRN H: Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am. J. Physiol. Renal Physiol. (2001) 280:F562-F573.
13. ISEKI K, IKEMIYA Y, ISEKI C, TAKISHITA S: Proteinuria and the risk of developing end-stage renal disease. Kidney Inc. (2003) 63:1468-1474.
14. VERHAVE JC, GANSEVOORT RT, HILLEGE HL, BAKKER SJ, DE ZEEUW D, DE JONG PE: An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int. Suppl. (2004) 92:S18-S21.
15. DECKERT T, FELDT-RASMUSSEN B, BORCH-JOHNSEN K, JENSEN T, KOFOED-ENEVOLDSEN A: Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia (1989) 32:219-226.
16. JENSEN JS: Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1324-1329.
17. FESTA A, D'AGOSTINO R, HOWARD G, MYKKANEN L, TRACY RP, HAFFNER SM: Inflammation and microalbuminuria in nondiabetic and Type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int. (2000) 58:1703-1710.
18. STEHOUWER CD, NAUTA JJ, ZELDENRUST GC, HACKENG WH, DONKER AJ, DEN OTTOLANDER GJ: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet (1992) 340:319-323.
19. CLAUSEN P, JENSEN JS, JENSEN G, BORCH-JOHNSEN K, FELDT-RASMUSSEN B: Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation (2001) 103:1869-1874.
20. JENSEN JS, BORCH-JOHNSEN K, JENSEN G, FELDT-RASMUSSEN B: Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin. Sci. (Lond) (1995) 88:629-633.
21. KLAUSEN KP, SCHARLING H, JENSEN G, JENSEN JS: New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension (2005) 46:33-37.
22. GERSTEIN HC, MANN JF, YI Q et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 286:421-426.
23. HILLEGE HL, FIDLER V, DIERCKS GF et al.: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 106:1777-1782.
24. BORCH-JOHNSEN K, FELDT-RASMUSSEN B, STRANDGAARD S, SCHROLL M, JENSEN JS: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1992-1997.
25. ROMUNDSTAD S, HOLMEN J, KVENILD K, HALLAN H, ELLEKJAER H: Microalbuminuria and all-cause mortality in 2089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am. J. Kidney Dis. (2003) 42:466-473.
26. DAMSGAARD EM, FROLAND A, JORGENSEN OD, MOGENSEN CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ (1990) 300:297-300.
27. JENSEN JS, FELDT-RASMUSSEN B, STRANDGAARD S, SCHROLL M, BORCH-JOHNSEN K: Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension (2000) 35:898-903.
28. WACHTELL K, IBSEN H, OLSEN MH et al.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. (2003) 139:901-906.
29. ASSELBERGS FW, DIERCKS GF, HILLEGE HL et al.: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation (2004) 110:2809-2816.
30. IBSEN H, OLSEN MH, WACHTELL K et al.: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 45:198-202.
31. VERHAVE JC, HILLEGE HL, BURGERHOF JG, NAVIS G, DE ZEEUW D, DE JONG PE: Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J. Am. Soc. Nephrol. (2003) 14:1330-1335.
32. ROSA TT, PALATINI P: Clinical value of microalbuminuria in hypertension. J. Hypertens. (2000) 18:645-654.
33. JENSEN JS, FELDT-RASMUSSEN B, BORCH-JOHNSEN K, CLAUSEN P, APPLEYARD M, JENSEN G: Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J. Hum. Hypertens. (1997) 11:727-732.
34. PARVING HH, MOGENSEN CE, JENSEN HA, EVRIN PE: Increased urinary albumin-excretion rate in benign essential hypertension. Lancet (1974) 1:1190-1192.
35. KNIGHT EL, KRAMER HM, CURHAN GC: High-normal blood pressure and microalbuminuria. Am. J. Kidney Dis. (2003) 41:588-595.
36. VERDECCHIA P, REBOLDI GP: Hypertension and microalbuminuria: the new detrimental duo. Blood Press. (2004) 13:198-211.
37. LEONCINI G, SACCHI G, VIAZZI F et al.: Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. J. Hypertens. (2002) 20:1315-1321.
38. BIDANI AK, GRIFFIN KA: Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension (2004) 44:595-601.
39. GRISK O, RETTIG R: Interactions between the sympathetic nervous systems and the kidneys in arterial hypertension. Cardiovasc. Res. (2004) 61:238-246.
40. PEDRINELLI R, PENNO G, DELL'OMO G et al.: Microalbuminuria and transcapillary albumin leakage in essential hypertension. Hypertension (1999) 34:491-495.
41. BOHLEN L, DE COURTEN M, WEIDMANN P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am. J. Hypertens. (1994) 7:84S-92S.
42. BAKRIS GL, FONSECA V, KATHOLI RE et al.: Differential effects of beta-blockers on albuminuria in patients with Type 2 diabetes. Hypertension (2005) 46:1309-1315.
43. JERUMS G, ALLEN TJ, CAMPBELL DJ et al.: Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Diabet. Med. (2004) 21:1192-1199.
44. WHITE WB, DUPREZ D, ST HILLAIRE R et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41:1021-1026.
45. BRANTSMA AH, BAKKER SJ, DE ZEEUW D, DE JONG PE, GANSEVOORT RT: Urinary albumin excretion as a predictor of the development of hypertension in the general population. J. Am. Soc. Nephrol. (2006) 17:331-335.
46. MOGENSEN CE: Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes (1990) 39:761-767.
47. SCHENA FP, GESUALDO L: Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. (2005) 16(Suppl. 1):S30-S33.
48. BOHLENDER JM, FRANKE S, STEIN G, Wolf G: Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. (2005) 289:F645-F659.
49. FERRANNINI E, BUZZIGOLI G, BONADONNA R et al.: Insulin resistance in essential hypertension. N. Engl. J. Med. (1987) 317:350-357.
50. BIANCHI S, BIGAZZI R, VALTRIANI C et al.: Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension (1994) 23:681-687.
51. GRANDI AM, SANTILLO R, ZANZI P et al.: Microalbuminuria in never-treated hypertensives: lack of relationship to hyperinsulinemia and genetic predisposition to hypertension. Am. J. Hypertens. (2000) 13:353-358.
52. GALL MA, HOUGAARD P, BORCH-JOHNSEN K, PARVING HH: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ (1997) 314:783-788.
53. RAVID M, BROSH D, RAVID-SAFRAN D, LEVY Z, RACHMANI R: Main risk factors for nephropathy in Type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Am. J. Kidney Dis. (1998) 158:998-1004.
54. CHATURVEDI N, FULLER JH, TASKINEN MR: Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of Type 1 diabetes. Diabetes Care (2001) 24:2071-2077.
55. CALVINO J, CALVO C, ROMERO R, GUDE F, SANCHEZ-GUISANDE D: Atherosclerosis profile and microalbuminuria in essential hypertension. Am. J. Kidney Dis. (1999) 34:996-1001.
56. CAMPESE VM, BIANCHI S, BIGAZZI R: Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int. Suppl. (1999) 71:S10-S13.
57. CIRILLO M, SENIGALLIESI L, LAURENZI M et al.: Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the Gubbio Population Study. Am. J. Kidney Dis. (1998) 158:1933-1939.
58. KLAHR S, SCHREINER G, ICHIKAWA I: The progression of renal disease. N. Engl. J. Med. (1988) 318:1657-1666.
59. TONOLO G, CICCARESE M, BRIZZI P, et al.: Reduction of albumin excretion rate in normotensive microalbuminuric Type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care (1997) 20:1891-1895.
60. ORTH SR: Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J. Am. Soc. Nephrol. (2004) 15(Suppl. 1):S58-S63.
61. HALIMI JM, PHILIPPON C, MIMRAN A: Contrasting renal effects of nicotine in smokers and non-smokers. Nephro. Dial. Transplant. (1998) 13:940-944.
62. CHASE HP, GARG SK, MARSHALL G et al.: Cigarette smoking increases the risk of albuminuria among subjects with Type 1 diabetes. JAMA (1991) 265:614-617.
63. CORRADI L, ZOPPI A, TETTAMANTI F, MALAMANI G, LAZZARI P, FOGARI R: Association between smoking and micro-albuminuria in hypertensive patients with Type 2 diabetes mellitus. J. Hypertens. Suppl. (1993) 11:S190-S191.
64. GERSTEIN HC, MANN JF, POGUE J et al.: Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care (2000) 23(Suppl. 2):B35-B39.
65. PINTO-SIETSMA SJ, MULDER J, JANSSEN WM, HILLEGE HL, DE ZEEUW D, DE JONG PE: Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann. Intern. Med. (2000) 133:585-591.
66. HILLEGE HL, JANSSEN WM, BAK AA et al.: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J. Intern. Med. (2001) 249:519-526.
67. ORTH SR, RITZ E: The renal risks of smoking: an update. Curr. Opin. Nephrol. Hypertens. (2002) 11:483-488.
68. CLELAND SJ, REID JL: The renin-angiotensin system and the heart: a historical review. Heart (1996) 76:7-12.
69. HARRIS P: Evolution and the cardiac patient. Cardiovasc. Res. (1983) 17:437-445.
70. SKEGGS LT, LENTZ KE, KAHN JR, SHUMWAY NP, WOODS KR: The amino acid sequence of hypertensin. II. J. Exp. Med. (1956) 104:193-197.
71. COATES D: The angiotensin converting enzyme (ACE). Int. J. Biochem. Cell Biol. (2003) 35:769-773.
72. STRUTHERS AD, MACDONALD TM: Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc. Res. (2004) 61:663-670.
73. DE GASPARO M, CATT KJ, INAGAMI T, WRIGHT JW, UNGER T: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. (2000) 52:415-472.
74. KAMBAYASHI Y, BARDHAN S, TAKAHASHI K et al.: Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. (1993) 268:24543-24546.
75. MURPHY TJ, ALEXANDER RW, GRIENDLING KK, RUNGE MS, BERNSTEIN KE: Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature (1991) 351:233-236.
76. CAMPBELL DJ: Tissue renin-angiotensin system: sites of angiotensin formation. J. Cardiovasc. Pharmacol. (1987) 10(Suppl. 7):S1-S8.
77. DZAU VJ: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation (1988) 77:14-113.
78. BADER M, PETERS J, BALTATU O, MULLER DN, LUFT FC, GANTEN D: Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J. Mol. Med. (2001) 79:76-102.
79. ZHUO JL, IMIG JD, HAMMOND TG, ORENGO S, BENES E, NAVAR LG: Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. Hypertension (2002) 39:116-121.
80. ICHIKAWI I, HARRIS RC: Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int. (1991) 40:583-596.
81. DZAU VJ, RE R: Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation (1994) 89:493-498.
82. WANG T, GIEBISCH G: Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney. Am. J. Physiol. (1996) 271:F143-F149.
83. NAVAR LG, HARRISON-BERNARD LM, IMIG JD, WANG CT, CERVENKA L, MITCHELL KD: Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J. Am. Soc. Nephrol. (1999) 10(Suppl. 12):S266-S272.
84. MONTANARI A, BIGGI A, CARRA N et al.: Endothelin-A receptors mediate renal hemodynamic effects of exogenous angiotensin II in humans. Hypertension (2003) 42:825-830.
85. WOLF G: Angiotensin II as a mediator of tubulointerstitial injury. Nephrol. Dial. Transplant. (2000) 15(Suppl. 6):61-63.
86. RUIZ-ORTEGA M, RUPEREZ M, ESTEBAN V et al.: Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol. Dial. Transplant. (2006) 21:16-20.
87. HOLLENBERG NK: Aldosterone in the development and progression of renal injury. Kidney Int. (2004) 66:1-9.
88. BOHRER MP, DEEN WM, ROBERTSON CR, BRENNER BM: Mechanism of angiotensin II-induced proteinuria in the rat. Am. J. Physiol (1977) 233:F13-F21.
89. LAPINSKI R, PERICO N, REMUZZI A, SANGALLI F, BENIGNI A, REMUZZI G: Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J. Am. Soc. Nephrol. (1996) 7:653-660.
90. GOMEZ-GARRE D, LARGO R, TEJERA N, FORTES J, MANZARBEITIA F, EGIDO J: Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension (2001) 37:1171-1178.
91. LEEHEY DJ, SINGH AK, ALAVI N, SINGH R: Role of angiotensin II in diabetic nephropathy. Kidney Int. Suppl. (2000) 77:S93-S98.
92. SUZUKI Y, RUIZ-ORTEGA M, LORENZO O, RUPEREZ M, ESTEBAN V, EGIDO J: Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. (2003) 35:881-900.
93. WILLIAMS B, BAKER AQ, GALLAGHER B, LODWICK D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension (1995) 25:913-917.
94. BALDONCINI R, DESIDERI G, BELLINI et al.: High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients. Kidney Int. (1999) 56:1499-1504.
95. PONTREMOLI R, SOFIA A, TIROTTA A et al.: The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J. Am. Soc. Nephrol. (1996) 7:2550-2558.
96. KARIO K, KANAI N, NISHIUMA S, FUJII T et al.: Hypertensive nephropathy and the gene for angiotensin-converting enzyme. Arterioscler. Thromb. Vasc. Biol. (1997) 17:252-256.
97. HADJADJ S, BELLOUM R, BOUHANICK B et al.: Prognostic value of angiotensin-I Converting enzyme I/D polymorphism for nephropathy in Type 1 diabetes mellitus: a prospective study. J. Am. Soc. Nephrol. (2001) 12:541-549.
98. PONTREMOLI R, RAVERA M, VIAZZI F et al.: Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension. Kidney Int. (2000) 57:561-569.
99. AMERICAN DIABETES ASSOCIATION: Standards of medical care in diabetes. Diabetes Care (2005) 28:S4-S36. Erratum in: Diabetes Care (2005) 28(4):990.
100. DE ZEEUW D, REMUZZI G, PARVING HH et al.: Proteinuria, a target for renoprotection in patients with Type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. (2004) 65:2309-2320.
101. ENGEL SL, SCHAEFFER TR, WAUGH MH, RUBIN B: Effects of the nonapeptide SQ-20881 on blood pressure of rats with experimental renovascular hypertension. Proc. Soc. Exp. Biol. Med. (1973) 143:483-487.
102. GAVRAS H, BRUNNER HR, LARAGH H, SEALEY JE, GAVRAS I, VUKOVICH RA: An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N. Engl. J. Med. (1974) 291:817-821.
103. GANSEVOORT RT, SLUITER WJ, HEMMELDER MH, DE ZEEUW D, DE JONG PE: Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol. Dial. Transplant. (1995) 10:1963-1974.
104. ACE INHIBITORS IN DIABETIC NEPHROPATHY TRIALIST GROUP: Should all patients with Type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann. Intern. Med. (2001) 134:370-379.
105. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. (1993) 329:1456-1462.
106. VIBERTI G, MOGENSEN CE, GROOP LC, PAULS JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA (1994) 271:275-279.
107. NO AUTHORS LISTED: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet (2000) 355:253-259.
108. RUGGENENTI P, FASSI A, ILIEVA AP et al.: Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. (2004) 351:1941-1951.
109. DALLA VM, POZZA G, MOSCA A et al.: Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr. Metab. (2004) 17:259-266.
110. NO AUTHORS LISTED: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet (1997) 349:1857-1863.
111. RUGGENENTI P, PERNAA, BENINI R et al.: In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigator of the GISEN group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J. Am. Soc. Nephrol. (1999) 10:997-1006.
112. STAESSEN JA, WANG JG, THIJS L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet (2001) 358:1305-1315.
113. FOX KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancer (2003) 362:782-788.
114. WING LM, REID CM, RYAN P et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. (2003) 348:583-592.
115. NISSEN SE, TUZCU EM, LIBBY P et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA (2004) 292:2217-2225.
116. DAHLOF B, SEVER PS, POULTER NR et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366:895-906.
117. PALS DT, MASUCCI FD, SIPOS F, DENNING GS Jr: A specific competitive antagonist of the vascular action of angiotensin. II. Circ.Res. (1971) 29:664-672.
118. KIDNEY DISEASE OUTCOMES QUALITY INITIATIVE (K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. (2004) 43:S1-S290.
119. BURNIER M, ZANCHI A: Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J. Hypertens. (2006) 24:11-25.
120. BERL T: Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist. J. Am. Soc. Nephrol. (2004) 15(Suppl. 1):S71-S76.
121. LANSANG MC, STEVANOVIC R, PRICE DA, LAFFEL LM, HOLLENBERG NK: ACE and non-ACE pathways in the renal vascular response to RAS interruption in Type 1 diabetes mellitus. Kidney Inc. (2005) 67:1033-1037.
122. BUTER H, NAVIS G, DULLAART RP, DE ZEEUW D, DE JONG PE: Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol. Dial. Transplant. (2001) 16:771-775.
123. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, GOMIS R, ANDERSEN S, ARNER P: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. (2001) 345:870-878.
124. LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoptotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345:851-860.
125. BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
126. VIBERTI G, WHEELDON NM: Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation (2002) 106:672-678.
127. BARNETT AH, BAIN SC, BOUTER P et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med. (2004) 351:1952-1961.
128. ZIAI F, OTS M, PROVOOST AP et al.: The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int. Suppl. (1996) 57:S132-S136.
129. NAKAYA H, SASAMURA H, KITAMURA Y et al.: Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Hypertens. Res. (1999) 22:303-312.
130. PLUM J, BUNTEN B, NEMETH R, GRABENSEE B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J. Am. Soc. Nephrol. (1998) 9:2223-2234.
131. GANSEVOORT RT, DEZEEUW D, DE JONG PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. (1994) 45:861-867.
132. CHAN JC, CRITCHLEY JA, TOMLINSON B, CHAN TY, COCKRAM CS: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am. J. Nephrol. (1997) 17:72-80.
133. NIELSEN S, DOLLERUP J, NIELSEN B, JENSEN HA, MOGENSEN CE: Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol. Dial. Transplant. (1997) 12(Suppl. 2):19-23.
134. HOLDAAS H, HARTMANN A, BERG KJ, LUND K, FAUCHALD P: Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol. Dial. Transplant. (1998) 13:3096-3102.
135. HERMIDA RC, CALVO C, AYALA DE, LOPEZ JE: Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension (2005) 46:960-968.
136. ISHIMITSU T, KOBAYASHI T, HONDAT et al.: Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens. Rev. (2005) 28:351-359.
137. VOGT L, NAVIS G, KOSTER J, MANOLIS AJ, REID JL, DE ZEEUW D: The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J. Hypertens. (2005) 23:2055-2061.
138. SONG JH, CHA SH, LEE HJ et al.: Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in Type 2 diabetic patients with advanced kidney disease. Nephrol. Dial. Transplant. (2006) 21:683-689.
139. FUJISAWA T, IKEGAMI H, ONO M et al.: Combination of half doses of angiotensin Type 1 receptor antagonist and angsotensin-converting enzyme inhibitor in diabetic nephropathy. Am. J. Hypertens. (2005) 18:13-17.
140. IBSEN H, WACHTELL K, OLSEN MH et al.: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J. Hypertens. (2004) 22:1805-1811.
141. BENSON SC, PERSHADSINGH HA, HO CI et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension (2004) 43:993-1002.
142. FLISER D, BUCHHOLZ K, HALLER H: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation (2004) 110:1103-1107.
143. EUROPEAN SOCIETY OF HYPERTENSION-EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES COMMITTEE: 2003 EUROPEAN SOCIETY Of HYPERTENSION-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1011-1053.
144. GREENE EL, KREN S, HOSTETTER TH: Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. (1996) 98:1063-1068.
145. QUAN ZY, WALSER M, HILL GS: Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. (1992) 41:326-333.
146. ROCHA R, STIER CT Jr, KIFOR I et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology (2000) 141:3871-3878.
147. HORIUCHI M, NISHIYAMA H, HAMA J et al.: Characterization of renal aldosterone receptors in genetically hypertensive rats. Am. J. Physiol. (1993) 264:F286-F291.
148. CONN JW, KNOPF RF, NESBIT RM: Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am. J. Surg. (1964) 107:159-172.
149. CHRYSOSTOMOU A, BECKER C: Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N. Engl. J. Med. (2001) 345:925-926.
150. SATO A, HAYASHI K, NARUSE M, SARUTA T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension (2003) 41:64-68.
151. ROSSING K, SCHJOEDT KJ, SMIDT UM, BOOMSMA F, PARVING HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care (2005) 28:2106-2112.
152. HAYASHI M, TSUTAMOTO T, WADA A et al.: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation (2003) 107:2559-2565.
153. PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341:709-717.
154. MACDONALD JE, KENNEDY N, STRUTHERS AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart (2004) 90:765-770.
155. EPSTEIN M: Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol. Dial. Transplant. (2003) 18:1984-1992.
156. WHITE WB, DUPREZ D, ST HILLAIRE R et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41:1021-1026.
157. BROWN NJ: Eplerenone: cardiovascular protection. Circulation (2003) 107:2512-2518.
158. PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348:1309-1321.
159. KOBAYASHI N, YOSHIDA K, NAKANO S et al.: Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension (2006) 47:671-679.
160. WOOD JM, MAIBAUM J, RAHUEL J et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. (2003) 308:698-705.
161. STANTON A, JENSEN C, NUSSBERGER J, O'BRIEN E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 42:1137-1143.
162. GRADMAN AH, SCHMIEDER RE, LINS RL, NUSSBERGER J, CHIANG Y, BEDIGIAN MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 111:1012-1018.
163. NUSSBERGER J, WUERZNER G, JENSEN C, BRUNNER HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP-100): comparison with enalapril. Hypertension (2002) 39:E1-E8.
164. AZIZI M, MENARD J, BISSERY A et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. (2004) 15:3126-3133.
165. PILZ B, SHAGDARSUREN E, WELLNER M et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension (2005) 46:569-576.
166. FISHER ND, HOLLENBERG NK: Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol. (2005) 16:592-599.
167. ATTHOBARI J, ASSELBERGS FW, BOERSMA C et al.: Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin. Ther. (2006) 28:432-444.
168. ROSSING K, SCHJOEDT KJ, JENSEN BR, BOOMSMA F, PARVING HH: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with Type 2 diabetes and microalbuminuria. Kidney Int. (2005) 68:1190-1198.
169. MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ (2000) 321:1440-1444.
170. NAKAO N, YOSHIMURA A, MORITA H, TAKADA M, KAYANO T, IDEURA T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancer (2003) 361:117-124.